Rituximab

About

Therapy type: Immunotherapy

Therapy strategy: CD20 inhibition

Mappings

NCI Thesaurus: Rituximab (coding:ncit:C1702)

RxNorm: rituximab (coding:rxcui:121191, coding:omop:1314273)

View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this therapy.

Organizations
Biomarkers
Cancer types
Therapies
Organizations Biomarkers Cancer types Therapies
FDA (2) CD20 + Non-Hodgkin Lymphoma Rituximab
FDA (2) CD20 + Non-Hodgkin Lymphoma Cyclophosphamide, Prednisolone, Rituximab, Vincristine
EMA (1) FDA (2) CD20 + Non-Hodgkin Lymphoma Cyclophosphamide, Doxorubicin, Prednisolone, Rituximab, Vincristine
FDA (2) CD20 + Non-Hodgkin Lymphoma Cyclophosphamide, Fludarabine, Mitoxantrone, Rituximab
FDA (4) CD20 + Non-Hodgkin Lymphoma Cyclophosphamide, Doxorubicin, Prednisone, Rituximab, Vincristine
FDA (2) CD20 + Diffuse Large B-Cell Lymphoma Cyclophosphamide, Doxorubicin, Prednisone, Rituximab, Vincristine
FDA (2) CD20 + Burkitt Lymphoma Cyclophosphamide, Doxorubicin, Prednisone, Rituximab, Vincristine
FDA (2) CD20 + Mature B-Cell Neoplasms Cyclophosphamide, Doxorubicin, Prednisone, Rituximab, Vincristine
FDA (2) CD20 + Chronic Lymphocytic Leukemia Cyclophosphamide, Fludarabine, Rituximab
EMA (1) CD20 + Diffuse Large B-Cell Lymphoma Corticosteroid, Cyclophosphamide, Cytarabine, Doxorubicin, Etoposide, Methotrexate, Rituximab, Vincristine
EMA (1) CD20 + Non-Hodgkin Lymphoma Corticosteroid, Cyclophosphamide, Cytarabine, Doxorubicin, Etoposide, Methotrexate, Rituximab, Vincristine
EMA (1) CD20 + Burkitt Lymphoma Corticosteroid, Cyclophosphamide, Cytarabine, Doxorubicin, Etoposide, Methotrexate, Rituximab, Vincristine
EMA (1) TP53 deletion Chronic Lymphocytic Leukemia Idelalisib, Rituximab
EMA (1) TP53 Somatic variants Chronic Lymphocytic Leukemia Idelalisib, Rituximab
EMA (1) 17p deletion Chronic Lymphocytic Leukemia Idelalisib, Rituximab